For dietary supplement brands, products containing peptides such as BPC-157 fall outside FDA regulations for supplements and are likely to trigger regulatory actions
Hill stresses that these uses are still being studied, and so far, evidence is limited or inconclusive
Weaknesses include pricing that surfaces mainly after intake, wide cost variance, and prescribing from a questionnaire without reading your genetics
Continuing research has shown that one of those medications has additional unexpected benefits
Weight loss Trulicity (dulaglutide) leads to some weight loss, but it is a secondary benefit of the medication
Given these single-agent efficacy profiles and the lack of comparative benefit data for combinations, current clinical consensus favors optimizing GLP-1 dosing before considering additional agents